TriangleBiopsy (NCT05570825)
Biopsy trial for Metastatic Lung Non-Small Cell Carcinoma (NCT05570825). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with metastatic or recurrent non-small-cell lung cancer, or stage IIIC unsuitable for curative local treatment. PD-L1 must be at least one percent; EGFR, ALK, ROS1, and RET drivers exclude participation.
The idea: oral SX-682 blocks CXCR1/2 signaling involved in immune suppression. It starts twice daily one week before three-weekly pembrolizumab infusions, which release a PD1 immune brake. Prior chemotherapy or immunotherapy for metastatic/recurrent disease is excluded.
This phase 2 study plans 30 patients. Christina Baik leads at Fred Hutch/University of Washington, Seattle, the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.